metabolic-research
Retatrutide
A triple-action GIP/GLP-1/glucagon receptor agonist representing the next generation of incretin pharmacology — under active clinical investigation for unprecedented effects on energy expenditure, hepatic fat oxidation, and body composition.
For research and laboratory use only. Not for human consumption.
Subscribe & save: $216
Quantity
Add 1 more to save 10% per unit
Technical Data
Specifications
Technical Details
Bulk Pricing
Volume Pricing Guide
Quality Assurance
Certificate of Analysis
Certificate of Analysis
COA documentation is being prepared for this product.
Contact research@roehnrx.com for batch-specific testing data.
Research Overview
About Retatrutide
Retatrutide (LY3437943) is a synthetic peptide engineered to simultaneously engage three metabolic receptor systems: GIP, GLP-1, and glucagon. The addition of glucagon receptor agonism to the dual-incretin framework introduces thermogenic and lipolytic mechanisms — glucagon signaling drives hepatic fat oxidation, increases energy expenditure, and promotes glycogenolysis — potentially amplifying weight reduction beyond what dual agonists achieve.
The tripartite mechanism is designed for complementary metabolic coverage: GLP-1 agonism suppresses appetite and slows gastric transit; GIP agonism modulates adipose metabolism and enhances insulin sensitivity; glucagon agonism increases basal energy expenditure and accelerates hepatic lipid clearance. Phase 2 clinical data have reported mean body weight reductions of 17–24% at higher doses, the largest treatment effects documented for any single pharmacological agent in obesity research.
ROEHN provides retatrutide at 99% HPLC-verified purity. As one of the most significant emerging compounds in metabolic peptide science, it is under active investigation for applications spanning metabolic-associated steatohepatitis (MASH), cardiovascular risk reduction, and preservation of lean mass during weight loss protocols.
